Health care stocks were flat to higher premarket Tuesday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) advancing by 0.7%.
Amylyx Pharmaceuticals (AMLX) shares were up more than 38% after the company said its investigational post-bariatric hypoglycemia treatment Avexitide met its primary endpoint in a phase 3 clinical trial.